ABSTRACT
INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous manifestations. The diagnosis of SLE is usually made when patients has developed four or more out of the eleven American College of Rheumatology (ACR) criteria [1] , which can range from different organ manifestations to production of various autoantibodies. Individual autoantibodies can be used to reflect or predict disease activity, and some are associated with specific disease manifestations [2, 3] .
Subsets of patients with distinct patterns of disease manifestations [4] [5] [6] and the clustering of autoantibodies [3, 7] have been previously reported, but seldom have these two phenomena been analyzed together. Identification of patient clusters by autoantibody profile, in addition to each cluster's associated features, may potentially be useful for disease prediction. For example, if tested positive for a certain autoantibody, a patient would likely belong to a certain cluster and thus more prone to develop other specific laboratory or clinical manifestations.
Cluster analysis is a statistical method which partitions cases by grouping them into clusters based on similarities between variables; in this study, different autoantibody production. However, cluster analysis does not provide an explanation as why these clusters exist, and techniques for determining the reliability and validity of clusters
have not yet been developed. Therefore separate association analysis between individual autoantibodies and clinical manifestations can also be performed.
In this study, we utilize cluster analysis to identify the existence of autoantibody clustering with specific subsets of clinical manifestations in Chinese SLE patients.
The predominant autoantibodies of each cluster were also individually associated with the over-represented clinical manifestations of the same cluster. Furthermore, there were significant associations between the representative manifestations of the same 5 and certain different clusters, which reiterated the observations in cluster analysis.
Our findings therefore suggest that autoantibody clustering and the grouping of clinical manifestations may be inter-related. 7 anti-Ro, anti-La and anti-ribonucleoprotein (anti-RNP). Patients were considered positive for certain disease manifestations as diagnosed by physicians in respective hospitals, and considered positive for autoantibodies if there were any positive results in previous serological tests performed at respective hospitals.
Statistical methods
Cluster analysis was performed using the K-means algorithm to group patients with similar autoantibody profiles together. However, K-means clustering is intended for clustering quantitative variables and the presence of autoantibody production is categorical. Factor analysis was therefore performed first with the factor loading scores used in the K-means algorithm. Further details on factor and cluster analyses can be found in the supplementary data and tables.
The frequencies of different autoantibodies and clinical manifestations between cluster groups were compared using the chi-square test with Yates' correction for overall p-values and the Fisher's exact test to compare between individual clusters. To compensate for the effect of multiple comparisons in the Fisher's exact tests, Bonferroni correction was used and only p-values <0.001 were considered significant.
Further association analyses using the chi-square test with Yates' correction were performed and odds ratios (OR) with 95% confidence intervals (CI) were used to quantify the relationship between individual autoantibodies and clinical manifestations, as well as between individual clinical manifestations. The Fisher's exact tests were used to calculate the p-values and, after Bonferroni correction, only p-values <0.001 were considered significant. SAS version 9.1 was used for calculating the Akaike's information criterion (AIC) and Bayesian information (BIC) criterion. SPSS version 11.5 was used for all other analyses.
RESULTS
A total of 1928 Chinese SLE patients from Hong Kong were studied. There were 1771 females and 157 males, making a female:male ratio of 11.3:1. The mean (SD) age of onset was 29.8 (13) years, and the mean (SD) disease duration for all patients was 13.1 (8.6) years.
Data regarding arthritis, serositis and neurological involvement were missing for 256 patients, thus any analyses involving these manifestations were calculated after exclusion of these patients. However since clustering was by autoantibody production only, and not clinical manifestations, this would not have any effect on clustering. All other data was otherwise available for 1928 patients. Baseline characteristics including prevalence of clinical manifestations and autoantibody profile in comparison to previous cohorts of other ethnicities are shown in Table 1 .
Autoantibody clusters and their differences in clinical manifestations
Using cluster analysis, the 1928 patients were grouped into three separate clusters of autoantibodies, and each cluster had significantly different subsets of clinical manifestations. The frequencies of individual autoantibodies and clinical manifestations in each respective cluster are shown in 
Associations between individual autoantibodies and clinical manifestations
Separate association analysis between individual autoantibodies and clinical manifestations echoed the previous observations from cluster analysis. Predominant autoantibodies showed associations with the over-represented clinical manifestations of the same cluster. The OR and CI are shown in Table 3 . For both Table 3 and Table   4 , the data has been presented so that the representative autoantibodies/clinical manifestations of each cluster (as identified by cluster analysis) are listed together for easier visualisation; no prior clustering was performed for this analysis. No associations between any autoantibodies and neurological involvement were found (data not shown).
Anti-dsDNA was positively associated with renal disorder (OR=2.37, CI=1.93-2.90) and negatively associated with photosensitivity (OR=0.68, CI=0.54-0.84).
Furthermore, renal disorder was not associated with all other autoantibodies from other clusters. This is consistent with the observations of Cluster 1 from previous cluster analysis. Serositis (OR=2.04, ) and haematological involvement (OR=1.56, CI=1.28-1.91) were exceptions and found to be positively associated with anti-dsDNA.
Anti-Sm, anti-RNP and aPL (predominant autoantibodies of Cluster 2) were individually associated with malar rash, arthritis and serositis (which were all representative clinical manifestations of the same cluster during cluster analysis), despite some associations failing to reach statistical significance after Bonferroni correction. These three autoantibodies also did not have associations with oral ulcers. Likewise, anti-Ro, and anti-La (characteristic autoantibodies of Cluster 3) were also associated with all the representative clinical manifestations of the same cluster, namely: discoid rash, photosensitivity and haematological involvement (although the associations of anti-La with discoid rash and photosensitivity were not significant).
Anti-Ro and anti-La also showed significant associations with the predominant clinical manifestations from Cluster 2. Anti-Ro was significantly associated with malar rash (OR=1.74, CI=1.45-2.09) and arthritis (OR=1.96, CI=1.61-2.40).
Associations between individual clinical manifestations
Individual association analysis was performed between different clinical manifestations. The OR and CI for all associations are shown in Table 4 . In most cases the associations were concordant with previous patterns. Renal disorder (Cluster 1) was negatively associated with all other manifestations, except with serositis (OR=1.56, CI=1.17-2.08) and haematological involvement (OR=1.01, CI=0.84-1.21).
However there were again much intra-and inter-cluster associations with the over- The demographics of the patients in this study (Table 1) Caucasians [10] . This is consistent with previous reports [12, 13] and it has been suggested that the presence of anti-Ro may contribute to the likelihood of developing renal involvement [14] . However this pattern is not consistent when Chinese patients are compared to African Blacks [11] . African Blacks had a higher frequency of anti-Ro (60.5%) despite a lower prevalence of renal disorder (48.6%). This is an important observation as renal disease is a major cause of morbidity in our SLE patients [15] and further research into the relationship between anti-Ro and renal involvement in Chinese patients would be of great value. Cluster 2 (anti-Sm/anti-RNP/aPL) had the highest prevalence of malar rash, oral ulcers, arthritis and serositis, and Cluster 3 (anti-Ro/anti-La) had the highest prevalence of discoid rash, photosensitivity and haematological involvement (Table 2) .
Although many associations remain controversial, these results were consistent with many previous reports. For example, in Cluster 2: the association between anti-RNP and arthritis [23] ; between anti-Sm and serositis [24] ; and in Cluster 3: between antiRo and photosensitivity [25] , discoid lupus and haematological involvement [26] .
There were many associations observed between Cluster 2 and Cluster 3, both between their over-represented clinical manifestations and autoantibodies (Table 3) , as well as between their clinical manifestations (Table 4 ). There were also consistently negative associations between these autoantibodies with renal disorder. In contrast, anti-dsDNA, the predominant autoantibody of Cluster 1, was strongly associated with renal disorder but seldom with the predominant features of other clusters. These observations make sense on both the autoantibody and clinical manifestation levels. On the autoantibody level, the pathogenic role for anti-dsDNA in renal involvement has been well established [27, 28] Of particular interest, this described subset of patients has shown to have greater prevalence of haematological involvement [6, 16] . This is again compatible with our results, where haematological involvement was an exception to the consistently negative associations observed with anti-dsDNA and renal disorder (Table 3 and   Table 4 ).
The prevalence of neurological involvement was not significantly different between clusters, and no association with other clinical manifestations were identified. This may be explained by the low prevalence of neurological involvement in patients of our locality (7.9%) compared with other ethnicities (e.g. African Blacks: 17.1%), which is consistent with previous reports [37, 38] .
In interpretation of the results of cluster and association analysis as a whole, this study Overall, in this study we observe that patients can be clearly separated into three clusters based in autoantibody profile. Although Cluster 2 and Cluster 3 clearly cluster very distinctly by autoantibody production, there is much overlapping of their representative clinical manifestations. These findings also suggest that SLE may be viewed as a disease with a bipolar spectrum of autoantibody and clinical manifestations; with these three clusters of patients viewed on two different ends of disease manifestations. On one end are patients from Cluster 1 (anti-dsDNA), with the most renal disorder but lowest prevalence of other manifestations. On the other end are patients of Cluster 2 (anti-Sm/anti-RNP/aPL) and Cluster 3 (anti-Ro/anti-La). The exceptions of haematological involvement and serositis may suggest that these manifestations overlap between these two extremes. Furthermore, neurological involvement may exist independently without any significant between clusters or particular autoantibody associations.
There are numerous limitations to this study. For example, patients in this study were recruited from regional hospitals and may lead to an over-representation of patients with more severe manifestations. This may explain the larger number of patients in Cluster 1 (n=1211) than in Cluster 2 (n=423) or Cluster 3 (n=294). Secondly, other than anti-Ro, anti-La and anti-RNP, data for other manifestations not included in the ACR criteria [1] or more detailed sub-classifications were unavailable. However, given the pervasive adoption of these criteria and being able to compare with other research, we believe the choice of studied variables were appropriate. Furthermore, as this is only an observational study, we also plan to use a predictive approach on an independent sample in future study in order to validate our clustering results.
In conclusion, these findings may help guide the future study of potential common pathogenic mechanisms within autoantibody clusters and their effect on disease manifestations. It would be interesting to explore if these relationships between clinical subsets and autoantibody clusters may extend to the genetic level, for example by using these clusters in subphenotype analysis in genetic association studies.
1.
Three autoantibody clusters with different subsets of clinical manifestations exist in Chinese SLE patients.
2.
SLE can be viewed as a bipolar spectrum of autoantibody and clinical manifestations. Results are displayed as the odds ratio (95% confidence interval) and p-value for each association.
* denotes associations reaching statistical significance (p<0.001) 1,2,3 denotes over-represented autoantibodies or clinical manifestations of Cluster 1, Cluster 2 or Cluster 3 from cluster analysis (Table 2) Bold text denotes associations between the over-represented clinical manifestations of the same cluster from cluster analysis ( Results are displayed as the odds ratio (95% confidence interval) and p-value for each association.
* denotes associations reaching statistical significance (p<0.001)
